Online inquiry

IVTScrip™ mRNA-Anti-IL5RA, BIW-8405(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4331MR)

This product GTTS-WQ4331MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL5RA gene. The antibody can be applied in Chronic Obstructive Pulmonary Disease (COPD) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000564.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3568
UniProt ID Q01344
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL5RA, BIW-8405(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ4331MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10228MR IVTScrip™ mRNA-Anti-RHD, LFB-R593(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA LFB-R593
GTTS-WQ9269MR IVTScrip™ mRNA-Anti-CEACAM5, IMMU-130(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA IMMU-130
GTTS-WQ12706MR IVTScrip™ mRNA-Anti-DLL4, OMP-21M18(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA OMP-21M18
GTTS-WQ15361MR IVTScrip™ mRNA-Anti-ENG, TRC-105(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA TRC-105
GTTS-WQ6013MR IVTScrip™ mRNA-Anti-IL12B, CNTO 1275(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA CNTO 1275
GTTS-WQ6795MR IVTScrip™ mRNA-Anti-ERBB2, DS-8201(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA DS-8201
GTTS-WQ11456MR IVTScrip™ mRNA-Anti-NT5E, MEDI-9447(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MEDI-9447
GTTS-WQ12581MR IVTScrip™ mRNA-Anti-Felcat NGF, NV-02(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA NV-02
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW